Journal articles on the topic 'BRAFV600E oncogene'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'BRAFV600E oncogene.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Algazi, Alain Patrick, Megan Othus, Benjamin Newell Voorhies, Kari Lynn Kendra, Shaker R. Dakhil, Amy K. Harker-Murray, Christopher D. Lao, et al. "Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 10059. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10059.
Rogounovitch, Tatiana I., Svetlana V. Mankovskaya, Mikhail V. Fridman, Tatiana A. Leonova, Victor A. Kondratovitch, Natalya E. Konoplya, Shunichi Yamashita, Norisato Mitsutake, and Vladimir A. Saenko. "Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus." Cancers 13, no. 13 (July 5, 2021): 3374. http://dx.doi.org/10.3390/cancers13133374.
Perna, Daniele, Florian A. Karreth, Alistair G. Rust, Pedro A. Perez-Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis, et al. "BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model." Proceedings of the National Academy of Sciences 112, no. 6 (January 26, 2015): E536—E545. http://dx.doi.org/10.1073/pnas.1418163112.
Kaabouch, Meryem, Hafsa Chahdi, Naima Azouzi, Mohammed Oukabli, Issam Rharrassi, Adil Boudhas, Hassan Jaddi, et al. "BRAFV600E hot spot mutation in thyroid carcinomas: first Moroccan experience from a single-institution retrospective study." African Health Sciences 20, no. 4 (December 16, 2020): 1849–56. http://dx.doi.org/10.4314/ahs.v20i4.40.
Wang, Liye, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang, and Fei Xu. "BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review." Oncology Research and Treatment 45, no. 1-2 (November 24, 2021): 54–61. http://dx.doi.org/10.1159/000520453.
Zurnadzhy, Liudmyla, Tetiana Bogdanova, Tatiana I. Rogounovitch, Masahiro Ito, Mykola Tronko, Shunichi Yamashita, Norisato Mitsutake, Serhii Chernyshov, Sergii Masiuk, and Vladimir A. Saenko. "The BRAFV600E Mutation Is Not a Risk Factor for More Aggressive Tumor Behavior in Radiogenic and Sporadic Papillary Thyroid Carcinoma at a Young Age." Cancers 13, no. 23 (November 30, 2021): 6038. http://dx.doi.org/10.3390/cancers13236038.
Hosier, Gregory W., and Matthew T. Roberts. "Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma." Canadian Urological Association Journal 10, no. 9-10 (September 13, 2016): 306. http://dx.doi.org/10.5489/cuaj.3652.
Chabanet, Tamer Basel, Shannon Steinberg, Peisheng Zhang, and Mary Jo Turk. "Elucidating the oncogene-driven regulatory T cell responses during melanoma tumorigenesis." Journal of Immunology 196, no. 1_Supplement (May 1, 2016): 74.1. http://dx.doi.org/10.4049/jimmunol.196.supp.74.1.
Kidger, Andrew M., Linda K. Rushworth, Julia Stellzig, Jane Davidson, Christopher J. Bryant, Cassidy Bayley, Edward Caddye, Tim Rogers, Stephen M. Keyse, and Christopher J. Caunt. "Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling." Proceedings of the National Academy of Sciences 114, no. 3 (January 4, 2017): E317—E326. http://dx.doi.org/10.1073/pnas.1614684114.
Spourquet, Catherine, Ophélie Delcorte, Pascale Lemoine, Nicolas Dauguet, Axelle Loriot, Younes Achouri, Maija Hollmén, et al. "BRAFV600E Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages." Cancers 14, no. 19 (September 26, 2022): 4687. http://dx.doi.org/10.3390/cancers14194687.
Lee, Min Hee, Seong Eun Lee, Dong Wook Kim, Min Jeong Ryu, Sung Jin Kim, Sung Joong Kim, Yong Kyoung Kim, et al. "Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E." Journal of Clinical Endocrinology & Metabolism 96, no. 1 (January 1, 2011): E19—E30. http://dx.doi.org/10.1210/jc.2010-1071.
von Soosten, Laura, Janina Haar, Veronika Frehtman, Stefan Holderbach, Julius Upmeier zu Belzen, Michael Jendrusch, Konstantin Okonechnikov, et al. "THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing." Neuro-Oncology 24, Supplement_1 (June 1, 2022): i185—i186. http://dx.doi.org/10.1093/neuonc/noac079.695.
Adamopoulos, Christos, Kostas A. Papavassiliou, Poulikos I. Poulikakos, and Athanasios G. Papavassiliou. "RAF and MEK Inhibitors in Non-Small Cell Lung Cancer." International Journal of Molecular Sciences 25, no. 9 (April 24, 2024): 4633. http://dx.doi.org/10.3390/ijms25094633.
Baldari, Silvia, Giuliana Di Rocco, Marie C. Heffern, Timothy A. Su, Christopher J. Chang, and Gabriele Toietta. "Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells." Cancers 11, no. 5 (May 12, 2019): 659. http://dx.doi.org/10.3390/cancers11050659.
Jiang, Cuiping, Lin Xie, Yiding Zhang, Masayuki Fujinaga, Wakana Mori, Yusuke Kurihara, Tomoteru Yamasaki, Feng Wang, and Ming-Rong Zhang. "Pharmacokinetic Evaluation of [11C]CEP-32496 in Nude Mice Bearing BRAFV600E Mutation-Induced Melanomas." Molecular Imaging 17 (January 1, 2018): 153601211879595. http://dx.doi.org/10.1177/1536012118795952.
Riesco-Eizaguirre, G., P. Gutiérrez-Martínez, M. A. García-Cabezas, M. Nistal, and P. Santisteban. "The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane." Endocrine-Related Cancer 13, no. 1 (March 2006): 257–69. http://dx.doi.org/10.1677/erc.1.01119.
Recagni, Tassinari, Doria, Cimino-Reale, Zaffaroni, Freccero, Folini, and Richter. "The Oncogenic Signaling Pathways in BRAF-Mutant Melanoma Cells are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands." Cells 8, no. 10 (October 18, 2019): 1274. http://dx.doi.org/10.3390/cells8101274.
Uribe-Alvarez, Cristina, Daniela Araiza-Olivera, Alexa Cannon, and Jonathan Chernoff. "Abstract 4747: Novel targets for BRAFV600E and BRAFV600ERAC1P29S drug resistant melanoma." Cancer Research 84, no. 6_Supplement (March 22, 2024): 4747. http://dx.doi.org/10.1158/1538-7445.am2024-4747.
Wongchenko, Matthew J., Antoni Ribas, Paolo A. Ascierto, Brigitte Dréno, Anna Maria di Giacomo, Claus Garbe, Ilsung Chang, et al. "Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study." JCO Precision Oncology, no. 2 (November 2018): 1–18. http://dx.doi.org/10.1200/po.17.00242.
Chaft, Jamie E., Scott Swanson, Jay M. Lee, Jules Lin, Hisashi Tsukada, Tianhong Li, R. Taylor Ripley, et al. "Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial." Journal of Clinical Oncology 42, no. 16_suppl (June 1, 2024): 8068. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8068.
Tosios, Konstantinos I., Eleni-Marina Kalogirou, and Ioannis G. Koutlas. "Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression." International Journal of Molecular Sciences 25, no. 4 (February 13, 2024): 2238. http://dx.doi.org/10.3390/ijms25042238.
Stocksdale, Brian, Yaping Joyce Liao, Gwen Coffey, and Seema Nagpal. "INNV-06. SECOND GENERATION BRAF/MEK INHIBITION IN ANAPLASTIC PLEOMORPHIC XANTHROASTROCYTOMA." Neuro-Oncology 22, Supplement_2 (November 2020): ii117—ii118. http://dx.doi.org/10.1093/neuonc/noaa215.490.
Dimitrion, Peter, Jugmohit Toor, James Ge, Qiyan Wang, Carl E. Allen, Li Zhou, and Qing-Sheng Mi. "HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes." Blood 142, Supplement 1 (November 28, 2023): 676. http://dx.doi.org/10.1182/blood-2023-185195.
Cangi, Maria Giulia, Riccardo Biavasco, Giulio Cavalli, Greta Grassini, Elena Dal-Cin, Corrado Campochiaro, Barbara Guglielmi, et al. "BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease." Annals of the Rheumatic Diseases 74, no. 8 (March 26, 2014): 1596–602. http://dx.doi.org/10.1136/annrheumdis-2013-204924.
Hassan, Alaa A., Nasr K. Mohamed, Ashraf A. Aly, Mohamed Ramadan, Hesham A. M. Gomaa, Ahmed T. Abdel-Aziz, Bahaa G. M. Youssif, Stefan Bräse, and Olaf Fuhr. "Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAFV600E." Molecules 28, no. 24 (December 5, 2023): 7951. http://dx.doi.org/10.3390/molecules28247951.
Sigaud, Romain, Florian Selt, Thomas Hielscher, Nina Overbeck, Diren Usta, Marc Remke, Daniel Picard, et al. "LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii368. http://dx.doi.org/10.1093/neuonc/noaa222.396.
Grob, Sydney, Lianna Nobre, Kurtis Davies, Scott Ryall, Dara Aisner, Lindsey Hoffman, Shadi Zahedi, et al. "LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii373. http://dx.doi.org/10.1093/neuonc/noaa222.416.
Sadangi, Shreyans, Katarina Milosavljevic, Edgardo Castro-Perez, Marcos Lares, Mithalesh Singh, Sarah Altameemi, David J. Beebe, Jose M. Ayuso, and Vijayasaradhi Setaluri. "Role of the Skin Microenvironment in Melanomagenesis: Epidermal Keratinocytes and Dermal Fibroblasts Promote BRAF Oncogene-Induced Senescence Escape in Melanocytes." Cancers 14, no. 5 (February 27, 2022): 1233. http://dx.doi.org/10.3390/cancers14051233.
Alaali, Lujain A., Ming Yuan, Chales Eberhart, and Eric Raabe. "Abstract 3414: The pan-RAF inhibitor tovorafenib suppresses NF1-mutant glioma through upregulation of FOXO1 and triggering of oncogene-induced senescence." Cancer Research 83, no. 7_Supplement (April 4, 2023): 3414. http://dx.doi.org/10.1158/1538-7445.am2023-3414.
Alaali, Lujain, Eric Raabe, Micah Maxwell, Charles Eberhart, and Hui Zhang. "DDDR-18. COMPREHENSIVE PROTEOMIC PROFILING OF BRAFV600E GLIOMA CELLS SHOWS UPREGULATION OF GLYCOLYSIS AND TCA CYCLE PROTEINS AFTER COMBINED MTOR AND MAP KINASE PATHWAY BLOCKADE." Neuro-Oncology 24, Supplement_7 (November 1, 2022): vii102. http://dx.doi.org/10.1093/neuonc/noac209.383.
Temprine, Kelsey, Nathaniel R. Campbell, Richard Huang, Erin M. Langdon, Theresa Simon-Vermot, Krisha Mehta, Averill Clapp, Mollie Chipman, and Richard M. White. "Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance." Science Signaling 13, no. 629 (April 28, 2020): eaau1453. http://dx.doi.org/10.1126/scisignal.aau1453.
Song, Kai, Jenna K. Minami, Arthur Huang, Siavash R. Dehkordi, Shirley H. Lomeli, Jens Luebeck, Mark H. Goodman, et al. "Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges." Cancer Discovery 12, no. 4 (December 20, 2021): 1046–69. http://dx.doi.org/10.1158/2159-8290.cd-20-0936.
Corso, Giovanni, Valeria Pascale, Giuseppe Flauti, Daniele Marrelli, and Franco Roviello. "Oncogenic mutations in colorectal cancer, indications for anatomical sites, and targeted intervention." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e22037-e22037. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22037.
Ngiow, Shin Foong, Katrina M. Meeth, Kimberley Stannard, Deborah S. Barkauskas, Gideon Bollag, Marcus Bosenberg, and Mark J. Smyth. "Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma." OncoImmunology 5, no. 3 (December 10, 2015): e1089381. http://dx.doi.org/10.1080/2162402x.2015.1089381.
Luciano, Angelo, Luigi Liguori, Giovanna Polcaro, Francesco Sabbatino, and Stefano Pepe. "Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review." Clinics and Practice 13, no. 6 (November 30, 2023): 1549–60. http://dx.doi.org/10.3390/clinpract13060136.
Drilon, Alexander E., Melissa Lynne Johnson, Shirish M. Gadgeel, Dale Nepert, Gang Feng, Marzieh Golmakani, Micaela Reddy, et al. "A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): 3020. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3020.
Robb, Ryan, Linlin Yang, Changxian Shen, Adam R. Wolfe, Amy Webb, Xiaoli Zhang, Marall Vedaie, et al. "Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair." Clinical Cancer Research 25, no. 15 (May 16, 2019): 4749–60. http://dx.doi.org/10.1158/1078-0432.ccr-18-3625.
Alotaibi, Sultan, Osama Alhafi, Hatem Nasr, Khalid Eltayeb, and Ghaleb Elyamany. "Erdheim-Chester Disease: Case Report with Aggressive Multisystem Manifestations and Review of the Literature." Case Reports in Oncology 10, no. 2 (June 14, 2017): 501–7. http://dx.doi.org/10.1159/000477336.
Dawar, Richa, Kunal Gawri, Estelamari Rodriguez, Deukwoo Kwon, Fahmin Basher, Philippos Apolinario Costa, Khadeja Khan, Tisdrey Torres, Chukwuemeka Ikpeazu, and Gilberto Lopes. "Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e21219-e21219. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21219.
Geisen, Mariah, Josiane weber-Tessmann, Courtney Kelson, Daheng He, Chi Wang, Abu Saleh Mosa Faisal, Jill Kolesar, and Yekaterina Zaytseva. "Abstract 4760: Inhibition of FASN postpones development of resistance to BRAF inhibitors in colorectal cancer." Cancer Research 84, no. 6_Supplement (March 22, 2024): 4760. http://dx.doi.org/10.1158/1538-7445.am2024-4760.
Riesco-Eizaguirre, Garcilaso, Irene Rodríguez, Antonio De la Vieja, Eugenia Costamagna, Nancy Carrasco, Manuel Nistal, and Pilar Santisteban. "The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer." Cancer Research 69, no. 21 (October 27, 2009): 8317–25. http://dx.doi.org/10.1158/0008-5472.can-09-1248.
Schott, M. "The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer." Yearbook of Endocrinology 2010 (January 2010): 154–55. http://dx.doi.org/10.1016/s0084-3741(10)79511-1.
Pricl, Sabrina, Erik Laurini, Domenico Marson, and Gabriele Cavalieri. "Abstract C153: Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations." Molecular Cancer Therapeutics 22, no. 12_Supplement (December 1, 2023): C153. http://dx.doi.org/10.1158/1535-7163.targ-23-c153.
Lim, Kee Siang, Zachary Wei Ern Yong, Huajing Wang, Tuan Zea Tan, Ruby Yun-Ju Huang, Daisuke Yamamoto, Noriyuki Inaki, et al. "Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells." Journal of Biological Chemistry 295, no. 19 (March 24, 2020): 6387–400. http://dx.doi.org/10.1074/jbc.ra120.012943.
Chan, Lai N., Christian Hurtz, Huimin Geng, Franziska Auer, Zhengshan Chen, Gang Xiao, Jae-Woong Lee, Kadriye Nehir Cosgun, B. Hilda Ye, and Markus Muschen. "Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling." Blood 132, Supplement 1 (November 29, 2018): 1336. http://dx.doi.org/10.1182/blood-2018-99-115514.
Liebig, Janika K., Silke Kuphal, and Anja Katrin Bosserhoff. "HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth." Cancers 12, no. 5 (May 21, 2020): 1299. http://dx.doi.org/10.3390/cancers12051299.
Kunz, Manfred, and Julio Vera. "Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers." Cancers 11, no. 4 (April 3, 2019): 465. http://dx.doi.org/10.3390/cancers11040465.
Groisberg, Roman, David S. Hong, Filip Janku, Yunfang Jiang, ChongJuan Wei, Daniel D. Karp, Apostolia Maria Tsimberidou, et al. "SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 2588. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2588.
Borgenvik, Anna, Sean Misek, Alexander Zhang, Ruth Fekade, Timothy Ragnoni, Aaron Fultineer, Kevin Zhou, et al. "LGG-29. BEYOND MAPK SIGNALING - GENOME-SCALE CRISPR/CAS9 SCREENS REVEAL NEW TARGETS FOR TREATMENT OF KIAA1549::BRAF-DRIVEN PEDIATRIC LOW-GRADE GLIOMA." Neuro-Oncology 26, Supplement_4 (June 18, 2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.422.
Lee, Joon-Hyop, Jiyoung Ahn, Won Seo Park, Eun Kyung Choe, Eunyoung Kim, Rumi Shin, Seung Chul Heo, et al. "Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study." Journal of Clinical Medicine 8, no. 1 (January 17, 2019): 111. http://dx.doi.org/10.3390/jcm8010111.